Research programme: gene therapeutics - Prevail Therapeutics
Alternative Names: Gene therapeutics- REGENXBIO/Prevail TherapeuticsLatest Information Update: 28 Aug 2023
At a glance
- Originator Prevail Therapeutics
- Class Antiparkinsonians; Gene therapies
- Mechanism of Action Gene transference; Glucosylceramidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Gaucher's disease; Lysosomal storage diseases; Parkinson's disease
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Gaucher's-disease in USA (Parenteral, Injection)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Parenteral, Injection)
- 28 May 2023 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA (Parenteral, Injection)